Rongchang Pharmaceutical

Explore the latest insights on Rongchang Pharmaceutical and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Rongchang Pharmaceutical’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

FDA Approves Bayer's Sunharbo (Asundexian) – World's First FXIa Inhibitor for Secondary Stroke Prevention
CompanyDrug

FDA Approves Bayer’s Sunharbo (Asundexian) – World’s First FXIa Inhibitor for Secondary Stroke Prevention

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for asundexian 50 mg tablets, under the brand name Sunharbo — the first…

Charles River to Acquire Frontage's Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Charles River to Acquire Frontage’s Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

CDE Opens Public Comment on 112th Draft Batch of Reference Preparations Catalogue for Chemical Generic Drugs

CDE Opens Public Comment on 112th Draft Batch of Reference Preparations Catalogue for Chemical Generic Drugs

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
RemeGen Licenses Global Rights to Rongchang's Pan‑RAS(ON) Inhibitor RCZY‑690 – Deal Value up to RMB 4.87 Billion
CompanyDeals

RemeGen Licenses Global Rights to Rongchang’s Pan‑RAS(ON) Inhibitor RCZY‑690 – Deal Value up to RMB 4.87 Billion